Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27747804 | 0.89 | GPR119 (0.46) | GPR119LIMK2TBK1SCN9A | |
| SCHEMBL27747830 | 0.81 | GPR119 (0.49) | GPR119LIMK2TBK1 | |
| SCHEMBL386691 | 0.80 | GPR119 (0.56) | GPR119 | |
| SCHEMBL27734776 | 0.80 | GPR119 (0.48) | GPR119LIMK2TBK1 | |
| SCHEMBL5889155 | 0.75 | GPR119 (0.53) | GPR119TBK1 | |
| SCHEMBL4263363 | 0.74 | GPR119 (0.51) | GPR119LIMK2TBK1 | |
| SCHEMBL391299 | 0.73 | GPR119 (0.46) | GPR119MAPTLIMK2TBK1SCN9A | |
| SCHEMBL388956 | 0.73 | GPR119 (0.46) | GPR119TBK1SCN9A | |
| SCHEMBL391077 | 0.73 | TBK1 (0.47) | GPR119LIMK2TBK1SCN9A | |
| SCHEMBL391594 | 0.72 | GPR119 (0.51) | GPR119LIMK2TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101420941-A | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, and related combination therapies | ARENA PHARM INC (US) | 2009-04-29 | — | — | CN | disclosed |